REGN) has never split its shares. That’s not entirely surprising: It traded under $30 for most of its first 26 years on the public markets, and its shares only recently …
share split
Biotech stocks are volatile by nature, especially the high-dollar ones. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is one that sees massive moves in …
This implies a 2017 forward P/E for shares at 36x and PEG 1.9. REGN has return on equity of 22.3%, return on assets of 13%, and return on capital of 22%. Improving …
earnings
On the stock market today, Regeneron stock rose 0.1% to 461.37, as Sanofi stock fell 0.2% to 49.07. Shares of rivals Amgen and AbbVie were up 0.7% and 0.6%, …
Rheumatoid Arthritis
REGN) from a hold rating to a buy rating in a report released on Friday, May 5th. They currently have $484.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $375.00. REGN has been the subject …
BNS10d
Regeneron
Regeneron Sanofi RA Drug Gets FDA Nod Second Time Round: It proved to be second time lucky for Regeneron and partner Sanofi with the companies gaining FDA approval for their RA treatment, Kevzara. The companies had got a …
NASDAQ
Sanofi and Regeneron expect to announce results from their cardiovascular ... 10 stocks we like better than Sanofi When investing geniuses David and Tom …
Cholesterol
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported earnings on May 4, 2017, and although it missed on the bottom line, REGN stock is still surging higher by 5.51% on the back of a positive reinforcement of forward guidance. I …
NASDAQ
On the sell side, Fidelity reduced its positions in Chevron (CVX), currently trading at about $104 a share; Regeneron Pharmaceuticals (REGN ... can be a big part of …
American Funds